⌘K
t
ProBiotix Health plc (PBX) noted a recent fall in its share price on 16 February 2026. The Company's Directors stated they know of no fundamental commercial or operational reasons for this movement. ProBiotix also confirmed that its trading momentum remains strong, consistent with its update issued on 21 January 2026.
| Date | 16 Feb 2026 |
| Time | 12:30:00 |
| Category | Miscellaneous |
| ID | 1950T |
16 February 2026
ProBiotix Health plc
("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")
Statement regarding Share Price Movement
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, notes the recent fall in the Company's share price.
The Directors of the Company know of no fundamental commercial or operational reasons for this movement, which the Directors believe may result from mistaken assumptions about recent events at SkinBioTherapeutics plc (SBTX).
ProBiotix and SBTX were originally both formed by OptiBiotix Health plc (OPTI), and OPTI remains a significant shareholder in both companies.
Beyond that, there are no commercial or operational links between ProBiotix and SBTX, and recent events at SBTX have no bearing whatsoever on the business of the Company.
Further to the update issued by ProBiotix on 21 January 2026, the Board is pleased to confirm that trading momentum remains as strong as previously reported, and we look forward to updating our shareholders on our progress.
For further information, please contact:
|
ProBiotix Health plc |
|
|
|
investors@probiotixhealth.com |
|
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
|
|
|
|
|
AlbR Capital Limited
Aquis Corporate Adviser and Broker |
Tel: 020 7469 0930 |
|
|
|
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Notes to Editors:
ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a singular approach: discovering groundbreaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.